just providing some food for thought... sometimes you find...

just providing some food for thought... sometimes you find things where you would not expect...

https://www.researchgate.net/publication/26774459_CD4CD25_regulatory_T_cells_modulate_human_dendritic_cell_chemokines_via_multiple_mechanisms


he's been at it for a while,

Frédéric Triebel founded Immutep in 2001 with John Hawken, a bioentrepreneur, to acquire the intellectual property which Triebel had created with INSERM and the Institut Gustave Roussy related to LAG3 and then move LAG3-based products into the clinic. Serono granted an exclusive worldwide license. The company raised €2.5m in venture capital in late 2003[13] and another €2.5m in January 2005.[14] Between 2001 and 2014 Immutep scientists did further basic and applied research on LAG3 and also completed a number of clinical studies, most notable in metastatic renal cell carcinoma in 2009[15] and metastatic breast cancer in 2010.[16] Immutep was sold to Prima BioMed in 2014 for US$25m.[17]

bold above by me

when you read this document.. you may just see a similar finding that is required as noted in the lancet article...

it's the name of the game. get it going or slow it down... taken to extremes... not healthy...

sometimes you find things where you would not expect....

ARTHRITIS & RHEUMATISM Vol. 60, No. 9, September 2009, pp 2848–2854© 2009, American College of Rheumatology

This line of products is useful for many conditions...

It's all about the IP...

When the products hit the market.. we will be shown the IP....